RPRX

Royalty Pharma plc
D

RPRX

48.565
USD
0.07
(0.13%)
مغلق
حجم التداول
74,756
الربح لكل سهم
2
العائد الربحي
1.84
P/E
27
حجم السوق
20,806,149,892
أصول ذات صلة المقالات

العنوان: Royalty Pharma plc

القطاع: Healthcare
الصناعة: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.